To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Design-corrected variatio… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.

Journal article
Authors Matti Hakama
Sue M Moss
Ulf-Hakan Stenman
Monique J Roobol
Marco Zappa
Sigrid Carlsson
Marco Randazzo
Vera Nelen
Jonas Hugosson
Published in Journal of medical screening
Volume 24
Issue 2
Pages 98-103
ISSN 1475-5793
Publication year 2017
Published at Institute of Clinical Sciences, Department of Urology
Pages 98-103
Language en
Subject categories Urology and andrology, Urology and Nephrology, Cancer and Oncology


To calculate design-corrected estimates of the effect of screening on prostate cancer mortality by centre in the European Randomised Study of Screening for Prostate Cancer (ERSPC).The ERSPC has shown a 21% reduction in prostate cancer mortality in men invited to screening with follow-up truncated at 13 years. Centres either used pre-consent randomisation (effectiveness design) or post-consent randomisation (efficacy design).In six centres (three effectiveness design, three efficacy design) with follow-up until the end of 2010, or maximum 13 years, the effect of screening was estimated as both effectiveness (mortality reduction in the target population) and efficacy (reduction in those actually screened).The overall crude prostate cancer mortality risk ratio in the intervention arm vs control arm for the six centres was 0.79 ranging from a 14% increase to a 38% reduction. The risk ratio was 0.85 in centres with effectiveness design and 0.73 in those with efficacy design. After correcting for design, overall efficacy was 27%, 24% in pre-consent and 29% in post-consent centres, ranging between a 12% increase and a 52% reduction.The estimated overall effect of screening in attenders (efficacy) was a 27% reduction in prostate cancer mortality at 13 years' follow-up. The variation in efficacy between centres was greater than the range in risk ratio without correction for design. The centre-specific variation in the mortality reduction could not be accounted for by the randomisation method.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?